BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/21/2020 3:38:05 PM | Browse: 890 | Download: 1869
 |
Received |
|
2020-05-10 05:20 |
|
Peer-Review Started |
|
2020-05-10 05:21 |
|
First Decision by Editorial Office Director |
|
2020-06-13 02:10 |
|
Return for Revision |
|
2020-06-13 02:10 |
|
Revised |
|
2020-06-24 17:39 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-09-24 10:57 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-09-25 05:32 |
|
Articles in Press |
|
2020-09-25 05:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-10-20 11:40 |
|
Publish the Manuscript Online |
|
2020-10-21 15:38 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Real-world treatment attrition rates in advanced esophagogastric cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Erica S Tsang, Howard J Lim, Daniel J Renouf, Janine M Davies, Jonathan M Loree and Sharlene Gill |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Sharlene Gill, MD, Doctor, Doctor, Medicine, BC Cancer, 600 West 10th Avenue, Vancouver V5Z 4E6, Canada. sgill@bccancer.bc.ca |
| Key Words |
Esophagogastric cancer; Gastric cancer; Treatment attrition; Systemic therapy; Treatment outcomes; Real-world evidence |
| Core Tip |
Despite the availability of later lines of therapy for esophagogastric cancer (EGC), there remains limited real-world data about the treatment attrition rates between lines of therapy. In this population-based analysis, we characterize the use and treatment attrition rates for patients with advanced EGC. Among 245 patients, there was a high level of treatment attrition, with 50% receiving one line of therapy, 34% receiving two lines, and 14% receiving three-lines. Improved survival was associated with better baseline Eastern Cooperative Oncology Group and increased lines of therapy. This real-world analysis demonstrating such steep attrition rates highlights the unmet need for more efficacious early-line treatment options. |
| Publish Date |
2020-10-21 15:38 |
| Citation |
Tsang ES, Lim HJ, Renouf DJ, Davies JM, Loree JM, Gill S. Real-world treatment attrition rates in advanced esophagogastric cancer. World J Gastroenterol 2020; 26(39): 6027-6036
|
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i39/6027.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i39.6027 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
